| Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies W Schaefer, JT Regula, M Bähner, J Schanzer, R Croasdale, H Dürr, ... Proceedings of the National academy of Sciences 108 (27), 11187-11192, 2011 | 524 | 2011 |
| Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties C Klein, A Lammens, W Schäfer, G Georges, M Schwaiger, E Mössner, ... MAbs 5 (1), 22-33, 2013 | 366 | 2013 |
| Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies G Niederfellner, A Lammens, O Mundigl, GJ Georges, W Schaefer, ... Blood, The Journal of the American Society of Hematology 118 (2), 358-367, 2011 | 299 | 2011 |
| Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies C Klein, C Sustmann, M Thomas, K Stubenrauch, R Croasdale, ... MAbs 4 (6), 653-663, 2012 | 264 | 2012 |
| Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2, 3-dihydrothiazolo [2, 3-a] isoindol-5 (9bH)-ones and related compounds with anti-HIV-1 activity A Mertens, H Zilch, B Koenig, W Schaefer, T Poll, W Kampe, H Seidel, ... Journal of medicinal chemistry 36 (17), 2526-2535, 1993 | 238 | 1993 |
| Interactions between nonconjugated. pi.-systems R Gleiter, W Schaefer Accounts of chemical research 23 (11), 369-375, 1990 | 226 | 1990 |
| Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations W Schaefer, WG Friebe, H Leinert, A Mertens, T Poll, W Von der Saal, ... Journal of medicinal chemistry 36 (6), 726-732, 1993 | 188 | 1993 |
| The use of CrossMAb technology for the generation of bi-and multispecific antibodies C Klein, W Schaefer, JT Regula MAbs 8 (6), 1010-1020, 2016 | 184 | 2016 |
| Bivalent, bispecific antibodies C Klein, W Schaefer US Patent 8,242,247, 2012 | 150 | 2012 |
| The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern U Grauschopf, H Lilie, K Honold, M Wozny, D Reusch, A Esswein, ... Biochemistry 39 (30), 8878-8887, 2000 | 142 | 2000 |
| Bivalent, bispecific antibodies C Klein, W Schaefer US Patent 8,242,247, 2012 | 138 | 2012 |
| Bivalent, bispecific antibodies C Klein, W Schaefer US Patent 8,242,247, 2012 | 138 | 2012 |
| Engineering therapeutic bispecific antibodies using CrossMab technology C Klein, W Schaefer, JT Regula, C Dumontet, U Brinkmann, M Bacac, ... Methods 154, 21-31, 2019 | 127 | 2019 |
| In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor A Bazarsuren, U Grauschopf, M Wozny, D Reusch, E Hoffmann, ... Biophysical chemistry 96 (2-3), 305-318, 2002 | 125 | 2002 |
| Bivalent, bispecific antibodies C Klein, W Schaefer US Patent 8,227,577, 2012 | 121 | 2012 |
| Bivalent, bispecific antibodies C Klein, W Schaefer US Patent 9,266,967, 2016 | 119 | 2016 |
| Crystal structures of active SRC kinase domain complexes CB Breitenlechner, NA Kairies, K Honold, S Scheiblich, H Koll, E Greiter, ... Journal of molecular biology 353 (2), 222-231, 2005 | 102 | 2005 |
| Bispecific, tetravalent antigen binding proteins S Imhof-Jung, C Klein, JT Regula, W Schaefer, JM Schanzer US Patent 8,703,132, 2014 | 86 | 2014 |
| Bispecific anti-VEGF/anti-ANG-2 antibodies M Baehner, U Brinkmann, G Georges, RA Griep, S Imhof-Jung, A Kavlie, ... US Patent 8,268,314, 2012 | 85 | 2012 |
| Tri-or tetraspecific antibodies R Croasdale, C Klein, W Schaefer, JM Schanzer US Patent 8,796,424, 2014 | 79 | 2014 |
